Drug Action
Larotrectinib is a tropomyosin receptor kinase inhibitor.
PDF page 1064
Loading InternPractice…
Drug reference
Larotrectinib is a tropomyosin receptor kinase inhibitor.
PDF page 1064
Solid tumours with neurotrophic tyrosine receptor kinase gene fusion (initiated by a specialist) ▶BY MOUTH ▶Adult: 100 mg twice daily, for dose adjustments, treatment interruption, or discontinuation due to side- effects—consult product literature
PDF page 1064
DUE TO INTERACTIONS ▶Manufacturer advises if concomitant use with potent CYP3A4 inhibitors is unavoidable, reduce dose by 50%.
PDF page 1064
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
PDF page 1064
→Appendix 1: larotrectinib
PDF page 1064
▶Common or very common Anaemia. constipation. dizziness. fatigue. gait abnormal. leucopenia. muscle weakness. myalgia. nausea. neutropenia. paraesthesia. taste altered. vomiting. weight increased
PDF page 1064
Manufacturer advises effective contraception in females of childbearing potential and in men with a partner of childbearing potential, during treatment and for 1 month after last treatment; additional barrier method recommended in women using hormonal contraceptives. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1064
Manufacturer advises avoid—limited information available. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 1064
Manufacturer advises avoid during treatment and for 3 days after last treatment—no information available.
PDF page 1064
Manufacturer advises caution in moderate to severe impairment (increased risk of exposure). Dose adjustments Manufacturer advises dose reduction by 50 % in moderate to severe impairment.
PDF page 1064
Manufacturer advises monitor liver function (including ALT and AST) at baseline, then monthly during the first 3 months of treatment, and periodically thereafter; more frequent monitoring should be performed in patients who develop transaminase elevations. Treatment should be withheld or permanently discontinued based on severity—consult product literature. l HANDLING AND STORAGE For oral solution, manufacturer advises store in a refrigerator (2–8°C).
PDF page 1064
There can be variation in the licensing of different medicines containing the same drug. Oral solution EXCIPIENTS: May contain Hydroxybenzoates (parabens), potassium sorbate, propylene glycol, sorbitol, sucrose A ▶Vitrakvi (Bayer Plc) Larotrectinib (as Larotrectinib sulfate) 20 mg per 1 ml Vitrakvi 20mg/ml oral solution | 100 ml P £5,000.00 (Hospital only)
PDF page 1064
Driving and skilled tasks Manufacturer advises patients and carers should be counselled on the effects on driving and performance of skilled tasks—increased risk of dizziness and fatigue.
PDF page 1064
100 mg twice daily, for dose adjustments,
First-line fragment. Read the complete Indications and Dose section above.
PDF page 1064